{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:47:42Z","timestamp":1780577262143,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:00:00Z","timestamp":1555113600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00280-019-03834-1","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T08:02:30Z","timestamp":1555142550000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer"],"prefix":"10.1007","volume":"84","author":[{"given":"Mayumi","family":"Kobayashi-Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-6977","authenticated-orcid":false,"given":"Mayu","family":"Yunokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Bun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Miyasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,13]]},"reference":[{"issue":"4","key":"3834_CR1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/IGC.0000000000001222","volume":"28","author":"R Parikh","year":"2018","unstructured":"Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA (2018) Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: a retrospective medical record review. Int J Gynecol Cancer 28(4):738\u2013748. \n                    https:\/\/doi.org\/10.1097\/IGC.0000000000001222","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"3834_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ygyno.2016.05.020","volume":"142","author":"K Slaughter","year":"2016","unstructured":"Slaughter K, Holman LL, Thomas EL, Gunderson CC, Lauer JK, Ding K, McMeekin DS, Moore KM (2016) Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol 142(2):225\u2013230. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.020","journal-title":"Gynecol Oncol"},{"issue":"9698","key":"3834_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Japanese Gynecologic Oncology G (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331\u20131338. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)61157-0","journal-title":"Lancet"},{"issue":"26","key":"3834_CR4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology G (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473\u20132483. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1104390","journal-title":"N Engl J Med"},{"issue":"26","key":"3834_CR5","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, Investigators I (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484\u20132496. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1103799","journal-title":"N Engl J Med"},{"issue":"20","key":"3834_CR6","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323\u20133329. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.25.7519","journal-title":"J Clin Oncol"},{"issue":"17","key":"3834_CR7","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039\u20132045. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.42.0505","journal-title":"J Clin Oncol"},{"issue":"3","key":"3834_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis A, Tinker AV, Friedlander M (2014) \"Platinum resistant\" ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 133(3):624\u2013631. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2014.02.038","journal-title":"Gynecol Oncol"},{"issue":"14","key":"3834_CR9","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/14656566.2017.1328055","volume":"18","author":"F Tomao","year":"2017","unstructured":"Tomao F, Marchetti C, Romito A, Di Pinto A, Di Donato V, Capri O, Palaia I, Monti M, Muzii L, Benedetti Panici P (2017) Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. Expert Opin Pharmacother 18(14):1443\u20131455. \n                    https:\/\/doi.org\/10.1080\/14656566.2017.1328055","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"3834_CR10","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","volume":"21","author":"GC Stuart","year":"2011","unstructured":"Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E, Participants of 4th Ovarian Cancer Consensus C, Gynecologic Cancer I (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21(4):750\u2013755. \n                    https:\/\/doi.org\/10.1097\/IGC.0b013e31821b2568","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"3834_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"13","key":"3834_CR12","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302\u20131308. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.51.4489","journal-title":"J Clin Oncol"},{"issue":"1","key":"3834_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2017.11.008","volume":"148","author":"M Champer","year":"2018","unstructured":"Champer M, Huang Y, Hou JY, Tergas AI, Burke WM, Hillyer GC, Ananth CV, Neugut AI, Hershman DL, Wright JD (2018) Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecol Oncol 148(1):19\u201327. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2017.11.008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3834_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","volume":"150","author":"K Lindemann","year":"2018","unstructured":"Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study G, Harnett PR, Bowtell DDL, deFazio A (2018) Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol 150(2):239\u2013246. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.020","journal-title":"Gynecol Oncol"},{"key":"3834_CR15","first-page":"20","volume":"15","author":"ANGJTFDGDEPMEGAJ Lacave","year":"2001","unstructured":"Lacave ANGJTFDGDEPMEGAJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin. J Clin Oncol 15:20\u201328","journal-title":"J Clin Oncol"},{"issue":"1","key":"3834_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","volume":"143","author":"BJ Monk","year":"2016","unstructured":"Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM (2016) Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol 143(1):27\u201334. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.112","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3834_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2009.04.026","volume":"114","author":"W Meier","year":"2009","unstructured":"Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Luck HJ, Kimmig R, Pfisterer J (2009) Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum\/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGOOVAR). Gynecol Oncol 114(2):199\u2013205. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2009.04.026","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3834_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ygyno.2017.10.019","volume":"148","author":"FT Roncolato","year":"2018","unstructured":"Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M (2018) Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecol Oncol 148(1):36\u201341. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2017.10.019","journal-title":"Gynecol Oncol"},{"issue":"9","key":"3834_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/annonc\/mdw236","volume":"27","author":"F Trillsch","year":"2016","unstructured":"Trillsch F, Mahner S, Hilpert F, Davies L, Garcia-Martinez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E (2016) Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Ann Oncol 27(9):1733\u20131739. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw236","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03834-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T23:31:28Z","timestamp":1586647888000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03834-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,13]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3834"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03834-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,13]]},"assertion":[{"value":"28 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}